SCHEMBL6933173

SCHEMBL6933173

O=C1OC(c2ccc(-c3ccc(Cl)c(Cl)c3)cc2)C(O)=C1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
CYP1B1 Q16678 1/20 0.37
ESR2 Q92731 1/20 0.37
PTPN5 P54829 2/20 0.36
S1PR1 P21453 1/20 0.35
S1PR5 Q9H228 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
KMO O15229 1/20 0.35
SCN9A Q15858 1/20 0.35
PGR P06401 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7591786 1.00 AHR (0.41) AHRMEN1KMT2AHTTALDH1A1
SCHEMBL6929961 0.84 ALDH1A1 (0.47) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6929228 0.84 ALDH1A1 (0.47) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6931344 0.81 ALDH1A1 (0.45) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6930001 0.81 ALDH1A1 (0.45) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6025954 0.79 ALDH1A1 (0.46) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL7567210 0.79 ALDH1A1 (0.50) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6026250 0.79 ALDH1A1 (0.50) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL7567255 0.79 ALDH1A1 (0.50) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL6929995 0.79 SRD5A2 (0.43) AHRMEN1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US claimed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 AHR 4223/4885MEN1 1477/4885KMT2A 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.